Guggenheim made no change to the firm’s Buy rating on Zura Bio (ZURA), telling investors in a research note that the read-through from rival Acelyrin’s (SLRN) recent failure in hidradenitis suppurativa with izokibep is supportive of a broader MoA in HS. Zura is adding a B cell element to the already validated IL-17 approach in their lead asset ZB106, which is backed by encouraging data from a Syk inhibitor, the firm says, adding that Zura’s deal IL-17x BAFF approach could be promising in HS.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ZURA:
- Zura Bio enters sponsored research agreement with Benaroya Research Institute
- Oppenheimer Says These 2 Stocks Could Double Your Money — Here’s Why They Could Jump
- Netflix upgraded, Olaplex downgraded: Wall Street’s top analyst calls
- Zura Bio initiated with an Outperform at Oppenheimer
- Zura Bio price target raised to $22 from $20 at Raymond James
